A Novel Fibroblast Activation Protein‐Based Algorithm to Assess Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
Without a need for elastography, applying FAP Index following FIB-4 or NFS can facilitate accurate risk stratification of patients by greatly reducing the frequency of indeterminate results compared to FIB-4 or NFS alone, without compromising negative predictive value. Thus, FAP Index is a novel, fibrogenesis-relevant, rapid, robust diagnostic tool suited to increasing the efficiency of liver fibrosis triage in primary care.
Authors
- J. Richard George
- William W. Bachovchin (ORCID: https://orcid.org/0000-0002-9926-7244)
- Sarah E. Poplawski
- Pieter Van der Veken (ORCID: https://orcid.org/0000-0003-1208-3571)
- Harsha Chandraratna
- Kate Brewer
- Hui Zhang (ORCID: https://orcid.org/0000-0002-4699-4237)
- Leon A. Adams
- Torsten Pennell
- G J Ooi
- Geoffrey W. null McCaughan
- Jack Hung‐Sen Lai
- Avik Majumdar
- Diana Julie Leeming
- Mark D. Gorrell
- Mohammed Eslam
- Badwi B. Boumelhem
- Ziqi V. Wang
Institutions
- Tufts University (US)
- The University of Sydney (AU)
- University of Antwerp (BE)
- Charles Sturt University (AU)
- The University of Western Australia (AU)
- Royal Prince Alfred Hospital (AU)
- Austin Hospital (AU)
- Centenary Institute (AU)
- Western Australia Police (AU)
- Westmead Hospital (AU)
- Westmead Institute (AU)
- Nordic Bioscience (Denmark) (DK)
- Westmead Institute for Medical Research (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1111/jgh.70294
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- Hollywood Private Hospital Research Foundation
- Rebecca L. Cooper Medical Research Foundation
- University of Sydney
- Medical Research Council
- National Health and Medical Research Council